Condition: Premature Rupture of Membranes · Sponsor: Western Galilee Hospital-Nahariya
This prospective randomized controlled trial aims to evaluate whether intravenous administration of papaverine 12 hours after term PROM reduces the interval from membrane rupture to delivery and improves maternal and neonatal outcomes. Researchers will compare drug papaverine to a placebo
This description comes directly from the study's public registry record.
Maya Frank Wolf, professor · • 972:50-7887800 · mayaw@gmc.gov.il
Always discuss trial participation with your own doctor first.
| Galilee Medical Center | Nahariya, Israel, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07517796